Pulmonx Q3 net loss narrows 40% to $8.39 million

• Pulmonx’s third-quarter 2026 net loss narrowed 40% year over year to $8.4 million.
• Revenue rose 6% to $22.8 million, while operating expenses fell 18% to $24.9 million.
• International growth was tempered by no revenue from its China distributor while commercial activity restarts following registration renewal.
• Full-year 2026 revenue guidance remains $90 million to $92 million; operating expenses are now projected at $108 million to $109 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610271605PRIMZONEFULLFEED9853762) on October 27, 2026, and is solely responsible for the information contained therein.